Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
10 participants
Study Classification
INTERVENTIONAL
Study Start Date
2005-04-30
Study Completion Date
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Creatine Therapy for Huntington's Disease
NCT00026988
Huntington's Disease
COMPLETED
PHASE1/PHASE2
Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression
NCT05808153
Huntington Disease
RECRUITING
NA
Dynamic Neuroimaging Biomarkers in Huntington's Disease
NCT02639871
Brain Neuroimaging Biomarkers in Huntington Disease
COMPLETED
Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease
NCT01696708
Huntington Disease
COMPLETED
NA
A Clinical Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population
NCT02058654
Nutritional Status
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRÉCIS Protocol Title Creatine Safety \& Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety \& Tolerability Extension Study of Creatine in Subjects with HD
Study Phase Phase II Clinical Trial
Funding Departmental Funds
Drug Supply Provided By The Avicena Group, Inc (Palo Alto, CA)
Number of Subjects Up to 10 subjects enrolling from the creatine dose-finding study CREST-UP1 (PHRC Protocol: 2004-P-000925)
Number of Study Centers Single site
Study Period Approximately 306 weeks on study medication Approximately 310 weeks total including follow-up
Primary Objective To evaluate the long-term safety, tolerability and clinical impact of 30 grams per day of creatine.
Secondary Objective To serve as a basis for subsequent trials designed to specifically address creatine's ability to slow or halt the progression of HD
Primary Outcome Measure Primary purpose of this study is to estimate the proportion of subjects who find the drug intolerable.
Secondary Outcome Measures 1. Changes in UHDRS subscores
2\. Biological indicators that creatine might affect neuroprotection (serum creatine levels, absolute brain creatine concentrations) Significance/Relevance Several studies in rat and transgenic mouse models of HD have suggested that creatine may be neuroprotective. Most data on safety and tolerability of creatine have been performed in healthy athletes. Significant side effects were not found in studies of 14 days duration or less, while significant improvements in motor function have been shown in some studies of athletes, but not in others. There has been little data on safety and tolerability of creatine in disease conditions. In a Phase II study with HD subjects, we have found that 8g/day creatine taken over 16 weeks has been safe \& well tolerated.
Study Population All subjects enrolled in CREST-UP1 who continue to meet inclusion criteria are eligible. These are men and women \>18 years if age with a clinical diagnosis of HD will be considered. Sexually active women of childbearing potential may participate if they have a negative pregnancy test at screening and either use adequate birth control, are post-menopausal or are surgically sterile.
Study Design Open-label safety and tolerability study in subjects with HD enrolled at 1 site to receive creatine for approximately 306 weeks. All subjects enrolled in CREST-UP1 will be eligible to rollover into this study after the de-escalation phase; these subjects will receive 30 grams/day of creatine.
Eligibility Criteria Inclusion Criteria Subjects from CREST-UP1 eligible to continue on creatine in this extension study.
Subjects in Stage 1-3 of illness. Age of 18 years or older. Women of childbearing potential (i.e., those pre-menopausal or not surgically sterile) must confirm to the best of their knowledge that they are not pregnant or plan to get pregnant. Women of childbearing potential must have negative pregnancy test, be non-lactating and use adequate contraception methods. Adequate contraception methods include: oral birth control pills plus a barrier method (i.e. condoms, diaphragm), IUD or abstinence during the study. Abstinence will be considered an adequate contraception method on a case-to-case basis per site investigator's clinical assessment.
Subjects currently taking psychotropic medications (including antidepressants and neuroleptics) must be on stable dosages for at least 4 weeks prior to enrollment and should be maintained on constant dosage throughout the study. If clinical conditions mandate modifications of such medications, these changes will be systematically recorded and subject permitted to remain in the trial.
Subjects must be capable of providing informed consent and complying with trial procedures.
Subjects must be able to take oral medication. A person willing and able to serve as an informant and provide information about the daily dosing of study medication (if available).
Exclusion Criteria History of known sensitivity or intolerability to creatine. Subjects with underlying hematologic, hepatic or renal disease; screening white blood cell (WBC) count less than 3,800/mm3, screening creatinine greater than 2.25 or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal.
Clinical evidence of unstable medical illness in the investigator's judgment. History of renal impairment (moderate to severe). Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression or suicidal ideation within 90 days of the Baseline visit.
Current or history of substance (alcohol or drug) abuse within 1 year of the Baseline visit.
Pregnant women, or women who are currently breast-feeding. Subjects who are unable to tolerate an MRI scan.
Study Procedures: Prior to taking part in the CREST-X trial, both subject and responsible informant (if available) will be provided with information about the study and will be given time to decide whether they wish to participate.
Eligible subjects from the CREST-UP1 study who wish to continue on creatine will be given the option of rolling into this study after the de-escalation phase; subjects who do not wish to continue on creatine in this study will follow Washout procedures according to the CREST-UP1 protocol.
At Baseline (Visit 1) informed consent will be obtained from each subject. All inclusion/exclusion criteria will be reviewed to determine continued eligibility for the extension study. Additional assessments will include: past/current medication, vital signs/body weight/EKG, pregnancy test (females), blood/urine samples for clinical safety/research labs.
All subjects will receive a dose of 30 grams/day; a 6-month supply of study drug will be dispensed.
Subjects will be contacted by telephone at Week 3 (Phone 1) to assess compliance with trial medication, document adverse events, and changes to concomitant medications.
During the on-study drug period, eligible subjects will return for in-person visits at Week 6 (Visit 2), Week 16 (Visit 3), Week 24 (Visit 4), Week 36 (Visit 5), Week 64 (Visit 6), Week 88 (Visit 7), Week 112 (Visit 8), Week 136 (Visit 9), as well as for Visits 10-15 (Weeks 25-170 post Visit 9), and/or withdrawal, for the following evaluations: general medical exam, vital signs/body weight/EKG, review of concomitant medication, study drug compliance, adverse events, and clinical safety/research labs. UHDRS will be completed at Week 24 (Visit 4), Week 64 (Visit 6), Week 88 (Visit 7), Week 112 (Visit 8), and Week 136 (Visit 9) and Visits 10-15. MRI will be completed at Week 24 (Visit 4), Week 64 (Visit 6), Week 88 (Visit 7), Week 112 (Visit 8), and Week 136 (Visit 9) and Visits 10-15. Subjects will receive a new supply of study drug approximately every three months as needed.
Intermittent assessments during the on-study drug period will be completed at Week 9 (Phone 2), Week 18 (Phone 3), Week 30 (Phone 4), Week 52 (Phone 5), Week 76 (Phone 6), Week 100 (Phone 7), and Week 124 (Phone 8) to primarily evaluate compliance with trial medication (during on-study period), document adverse events, and changes to concomitant medications.
Subjects who demonstrate unexpected long-term toxicity or who no longer wish to remain in the study will proceed to Washout and be followed for eight weeks off-study drug.
At Phone Washout 1 (approximately 172 weeks post-Visit 9 subjects will be contacted by telephone primarily to document any adverse events and changes in concomitant medication during the washout period.
At Visit Washout 1 (approximately 174 weeks post-Visit 9 subjects will return for the following evaluations: general medical exam, vital signs/body weight/EKG, UHDRS, review of concomitant medication, adverse events, and clinical safety/research labs, and MRI.
Study Phase Phase II Clinical Trial
Funding Departmental Funds
Drug Supply Provided By The Avicena Group, Inc (Palo Alto, CA)
Number of Subjects Up to 10 subjects enrolling from the creatine dose-finding study CREST-UP1 (PHRC Protocol: 2004-P-000925)
Number of Study Centers Single site
Study Period Approximately 306 weeks on study medication Approximately 310 weeks total including follow-up
Primary Objective To evaluate the long-term safety, tolerability and clinical impact of 30 grams per day of creatine.
Secondary Objective To serve as a basis for subsequent trials designed to specifically address creatine's ability to slow or halt the progression of HD
Primary Outcome Measure Primary purpose of this study is to estimate the proportion of subjects who find the drug intolerable.
Secondary Outcome Measures 1. Changes in UHDRS subscores
2\. Biological indicators that creatine might affect neuroprotection (serum creatine levels, absolute brain creatine concentrations) Significance/Relevance Several studies in rat and transgenic mouse models of HD have suggested that creatine may be neuroprotective. Most data on safety and tolerability of creatine have been performed in healthy athletes. Significant side effects were not found in studies of 14 days duration or less, while significant improvements in motor function have been shown in some studies of athletes, but not in others. There has been little data on safety and tolerability of creatine in disease conditions. In a Phase II study with HD subjects, we have found that 8g/day creatine taken over 16 weeks has been safe \& well tolerated.
Study Population All subjects enrolled in CREST-UP1 who continue to meet inclusion criteria are eligible. These are men and women \>18 years if age with a clinical diagnosis of HD will be considered. Sexually active women of childbearing potential may participate if they have a negative pregnancy test at screening and either use adequate birth control, are post-menopausal or are surgically sterile.
Study Design Open-label safety and tolerability study in subjects with HD enrolled at 1 site to receive creatine for approximately 306 weeks. All subjects enrolled in CREST-UP1 will be eligible to rollover into this study after the de-escalation phase; these subjects will receive 30 grams/day of creatine.
Eligibility Criteria Inclusion Criteria Subjects from CREST-UP1 eligible to continue on creatine in this extension study.
Subjects in Stage 1-3 of illness. Age of 18 years or older. Women of childbearing potential (i.e., those pre-menopausal or not surgically sterile) must confirm to the best of their knowledge that they are not pregnant or plan to get pregnant. Women of childbearing potential must have negative pregnancy test, be non-lactating and use adequate contraception methods. Adequate contraception methods include: oral birth control pills plus a barrier method (i.e. condoms, diaphragm), IUD or abstinence during the study. Abstinence will be considered an adequate contraception method on a case-to-case basis per site investigator's clinical assessment.
Subjects currently taking psychotropic medications (including antidepressants and neuroleptics) must be on stable dosages for at least 4 weeks prior to enrollment and should be maintained on constant dosage throughout the study. If clinical conditions mandate modifications of such medications, these changes will be systematically recorded and subject permitted to remain in the trial.
Subjects must be capable of providing informed consent and complying with trial procedures.
Subjects must be able to take oral medication. A person willing and able to serve as an informant and provide information about the daily dosing of study medication (if available).
Exclusion Criteria History of known sensitivity or intolerability to creatine. Subjects with underlying hematologic, hepatic or renal disease; screening white blood cell (WBC) count less than 3,800/mm3, screening creatinine greater than 2.25 or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal.
Clinical evidence of unstable medical illness in the investigator's judgment. History of renal impairment (moderate to severe). Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression or suicidal ideation within 90 days of the Baseline visit.
Current or history of substance (alcohol or drug) abuse within 1 year of the Baseline visit.
Pregnant women, or women who are currently breast-feeding. Subjects who are unable to tolerate an MRI scan.
Study Procedures: Prior to taking part in the CREST-X trial, both subject and responsible informant (if available) will be provided with information about the study and will be given time to decide whether they wish to participate.
Eligible subjects from the CREST-UP1 study who wish to continue on creatine will be given the option of rolling into this study after the de-escalation phase; subjects who do not wish to continue on creatine in this study will follow Washout procedures according to the CREST-UP1 protocol.
At Baseline (Visit 1) informed consent will be obtained from each subject. All inclusion/exclusion criteria will be reviewed to determine continued eligibility for the extension study. Additional assessments will include: past/current medication, vital signs/body weight/EKG, pregnancy test (females), blood/urine samples for clinical safety/research labs.
All subjects will receive a dose of 30 grams/day; a 6-month supply of study drug will be dispensed.
Subjects will be contacted by telephone at Week 3 (Phone 1) to assess compliance with trial medication, document adverse events, and changes to concomitant medications.
During the on-study drug period, eligible subjects will return for in-person visits at Week 6 (Visit 2), Week 16 (Visit 3), Week 24 (Visit 4), Week 36 (Visit 5), Week 64 (Visit 6), Week 88 (Visit 7), Week 112 (Visit 8), Week 136 (Visit 9), as well as for Visits 10-15 (Weeks 25-170 post Visit 9), and/or withdrawal, for the following evaluations: general medical exam, vital signs/body weight/EKG, review of concomitant medication, study drug compliance, adverse events, and clinical safety/research labs. UHDRS will be completed at Week 24 (Visit 4), Week 64 (Visit 6), Week 88 (Visit 7), Week 112 (Visit 8), and Week 136 (Visit 9) and Visits 10-15. MRI will be completed at Week 24 (Visit 4), Week 64 (Visit 6), Week 88 (Visit 7), Week 112 (Visit 8), and Week 136 (Visit 9) and Visits 10-15. Subjects will receive a new supply of study drug approximately every three months as needed.
Intermittent assessments during the on-study drug period will be completed at Week 9 (Phone 2), Week 18 (Phone 3), Week 30 (Phone 4), Week 52 (Phone 5), Week 76 (Phone 6), Week 100 (Phone 7), and Week 124 (Phone 8) to primarily evaluate compliance with trial medication (during on-study period), document adverse events, and changes to concomitant medications.
Subjects who demonstrate unexpected long-term toxicity or who no longer wish to remain in the study will proceed to Washout and be followed for eight weeks off-study drug.
At Phone Washout 1 (approximately 172 weeks post-Visit 9 subjects will be contacted by telephone primarily to document any adverse events and changes in concomitant medication during the washout period.
At Visit Washout 1 (approximately 174 weeks post-Visit 9 subjects will return for the following evaluations: general medical exam, vital signs/body weight/EKG, UHDRS, review of concomitant medication, adverse events, and clinical safety/research labs, and MRI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Huntington's Disease (HD)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Creatine monohydrate
single arm long-term open label follow-up
Group Type
OTHER
Creatine monohydrate
Intervention Type
DRUG
Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Creatine monohydrate
Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
creatine, crea-pure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals who have completed the CREST-UP1 study.
* Individuals who are able to take oral medication.
* Individuals capable of providing informed consent and complying with trial procedures.
* Individuals who are able to take oral medication.
* Individuals capable of providing informed consent and complying with trial procedures.
Exclusion Criteria
* History of known sensitivity or intolerability to creatine.
* Clinical evidence of unstable medical illness in the investigator's judgment.
Additional eligibility criteria apply.
* Clinical evidence of unstable medical illness in the investigator's judgment.
Additional eligibility criteria apply.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Steven M. Hersch
Professor of Neurology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diana Rosas, MD, MS
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Steven M Hersch, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Charlestown, Massachusetts, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 2006 Jan 24;66(2):250-2. doi: 10.1212/01.wnl.0000194318.74946.b6.
Reference Type
BACKGROUND
Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K, Matson SA, Matson WR, Scherzer CR, Rosas HD, Hersch SM, Ferrante RJ. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim Biophys Acta. 2010 Jul-Aug;1802(7-8):673-81. doi: 10.1016/j.bbadis.2010.05.001. Epub 2010 May 9.
Reference Type
BACKGROUND
Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008 Apr;131(Pt 4):1057-68. doi: 10.1093/brain/awn025. Epub 2008 Mar 12.
Reference Type
BACKGROUND
Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003 Jun;85(6):1359-67. doi: 10.1046/j.1471-4159.2003.01706.x.
Reference Type
BACKGROUND
Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci. 2007 Nov 21;27(47):12908-15. doi: 10.1523/JNEUROSCI.4318-07.2007.
Reference Type
BACKGROUND
Hersch SM, Rosas HD. Neuroprotective therapy for Huntington's disease: new prospects and challenges. Expert Rev Neurother. 2001 Sep;1(1):111-8. doi: 10.1586/14737175.1.1.111.
Reference Type
BACKGROUND
Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11023-8. doi: 10.1073/pnas.0504921102. Epub 2005 Jul 25.
Reference Type
BACKGROUND
Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005 Nov;108(2):193-207. doi: 10.1016/j.pharmthera.2005.04.008. Epub 2005 Aug 1.
Reference Type
BACKGROUND
Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003.
Reference Type
BACKGROUND
Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci. 2008 Dec;1147:196-205. doi: 10.1196/annals.1427.034.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005P000530
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
NCT02956148
COMPLETED
EARLY_PHASE1
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626
NCT03810898
TERMINATED
EARLY_PHASE1
[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.
NCT02061722
COMPLETED
EARLY_PHASE1
iMagemHTT- 009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
NCT06634628
NOT_YET_RECRUITING
EARLY_PHASE1
Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.
NCT00468806
COMPLETED
PHASE1
Decoding Presymptomatic White Matter Changes in Huntington Disease
NCT03193099
COMPLETED
NA
Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage
NCT00598572
COMPLETED
PHASE1
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram
NCT00250172
COMPLETED
PHASE1
Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients
NCT06665880
NOT_YET_RECRUITING
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study
NCT00205582
UNKNOWN
PHASE1
A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants
NCT05320302
COMPLETED
PHASE1
Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations
NCT06191731
RECRUITING
NA
PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP
NCT00598390
COMPLETED
PHASE1
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants
NCT04911543
COMPLETED
PHASE1
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
NCT02633501
COMPLETED
PHASE2
A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662
NCT02194491
COMPLETED
PHASE1
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
NCT04141150
UNKNOWN
PHASE2
Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
NCT05573815
UNKNOWN
NA
Accelerated Diffusion MRI for Diagnosis of Hungtington Disease
NCT01884181
COMPLETED
Advanced Imaging Tools in the Study of Mild Traumatic Brain Injury
NCT01044615
COMPLETED
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
NCT00407576
COMPLETED
PHASE1
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
NCT00686504
COMPLETED
PHASE1
Brain Death: Inflammatory Response, Apoptosis, and Endotoxin Tolerance
NCT00615225
COMPLETED
Diffusion Tensor Imaging (DTI) in Infants With Krabbe Disease
NCT00787865
ACTIVE_NOT_RECRUITING